# Sapphiros grants Roche access to 1 billion lateral flow tests annually

Sapphiros announced a strategic supply and manufacturing option agreement with Roche, granting Roche exclusive rights to at least 1 billion lateral flow tests annually from Sapphiros' UK manufacturing facility, plus access to future molecular point-of-care tests.

- Type: Contract
- Announced: 2025-11-19
- Where: UK, United Kingdom
- Status: announced
- Capacity: 5 billion tests per year
- Products: lateral flow tests, molecular point-of-care tests
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Roche Holdings Inc](https://endata.com/companies/16415.md) (customer)
- [Sapphiros](https://endata.com/companies/88534.md) (supplier)

## Sources

- [sapphiros.com](https://www.sapphiros.com/media/sapphiros-announces-a-strategic-agreement-with-roche-providing-roche-access-to-1-billion-lateral-flow-tests-and-access-to-future-molecular-point-of-care-tests), 2025-11-19: "Agreement secures rapid, global access to tests for future pandemics and health emergencies"

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.